

UNCLASSIFIED

AD NUMBER
ADB257340
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Sep 99. Other requests shall be referred to US Army Medical Research and Materiel Comd., Fort Detrick, MD 21702-5012..
AUTHORITY
USAMRMC ltr, dtd 15 May 2003

THIS PAGE IS UNCLASSIFIED

AD _____

Award Number: DAMD17-97-1-7224

TITLE: Characterization of Breast Cancer Susceptibility Gene
BRCA2

PRINCIPAL INVESTIGATOR: Edward Lobenhofer, Ph.D.
Dr. Jeff Marks

CONTRACTING ORGANIZATION: Duke University Medical Center
Durham, North Carolina 27710

REPORT DATE: September 1999

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, September 1999). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DATA QUALITY INSPECTED

20000824 143

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-97-1-7224

Organization: Duke University Medical Center

Location of Limited Rights Data (Pages):

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

Patricia M. Madson 8/17/00 _____

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE September 1999	3. REPORT TYPE AND DATES COVERED Annual : (16 Aug 98 -15 Aug 99)	
4. TITLE AND SUBTITLE Characterization of Breast Cancer Susceptibility Gene BRCA2			5. FUNDING NUMBERS DAMD17-97-1-7224	
6. AUTHOR(S) Edward Lobenhofer ,Ph.D. Dr. Jeff Marks				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Duke University Medical Center Durham, North Carolina 27710 E-MAIL: Ek12@acpub.duke.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information, September 1999). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) Estrogen promotes proliferation in the MCF-7 breast cancer cell line via high levels of estrogen receptor. The primary mode of estrogen action has been considered to be through the transcriptional activation of gene containing estrogen response elements including the immediate early genes c-myc and fos. Recent reports have indicated that estrogen is capable of activating the MAPK cytoplasmic signaling cascade. In this study, specific small molecule inhibitors of MAPK (PD098059) and PI3-K (LY294002) activity were used to determine the influence of these cascades on estrogen-mediated mitogenesis. Both compounds decreased the fraction of cells entering DNA synthesis after treatment with 17β-estradiol. While a small decrease was noted in estrogen stimulated transcriptional activity, these drugs did not inhibit expression of myc or fos. However, both drugs did prevent the accumulation of cyclin D1, cdk2 activation, and hyperphosphorylation of the retinoblastoma protein indicating that the block occurred at, or prior to, this point in the cell cycle. Interestingly, the downstream targets of these kinase cascades, Erk1, Erk2, and PKB, were not activated over basal levels in response to estrogen treatment. These studies indicate that estrogen initiates mitogenesis by inducing the transcription of immediate early genes, but cytoplasmic signaling pathways play an important role in the control of subsequent events in the cell cycle.				
14. SUBJECT TERMS Estrogen, Proliferation, Breast Cancer, MAPK, PI3-K, Predoc Award				15. NUMBER OF PAGES 11
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Limited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

EKL Where copyrighted material is quoted, permission has been obtained to use such material.

EKL Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

EKL Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

NA In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

✓ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

NA In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

NA In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

NA In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Edward K. Lobenzky 9/13/99
PI - Signature Date

Table of Contents

Front Cover	1
Standard Form (SF) 298, Report Documentation Page	2
Foreward	3
Table of Contents	4
Introduction/Annual Summary	5
Appendix	10

Introduction/Summary of Last Year's Report

Last year's annual report detailed the completion of Specific Aim #1 (*develop key reagents in order to characterize the BRCA2 gene and protein*) as well as a substantial portion of Specific Aim #2 (*characterize the BRCA2 protein*). Pitfalls were also detailed explaining the refocusing of my research efforts from the hereditary/genetic basis for breast cancer to a concentration on the molecular mechanisms controlling estrogen's ability to function as a mitogen.

Estrogen acts to promote DNA synthesis in the MCF-7 human breast cancer cell line through high levels of estrogen receptor (ER). The primary mode of estrogen action has been considered to be through transcriptional activation of genes containing estrogen response elements including the immediate early genes *c-myc* and *c-fos* (1-3). After immediate early gene synthesis, the cell cycle converges on the expression and activity of the cyclins and the cyclin-dependent kinases (CDK), particularly the D-type cyclins. Cyclin D1 levels increase in response to mitogen stimulation, resulting in complex formation with either CDK4 or CDK6 (4, 5). This holoenzyme serves two functions: 1) sequestration of CDK inhibitors (such as *p27^{Kip1}* and *p21^{Cip1}*) from cyclin E, facilitating the formation of active cyclin E-CDK2 complexes, and 2) phosphorylation of the retinoblastoma (Rb) protein, which is also phosphorylated by cyclin E-CDK2 (6-8).

The activities of estrogen have generally been thought to occur primarily in the nucleus via interaction with its cognate nuclear receptor. Several recent reports have indicated that estrogen, acting through the estrogen receptor, is capable of inducing the mitogen-activated protein kinase (MAPK) cytoplasmic signaling cascade (9-13). Additional studies have shown that estrogen stimulates the production of phosphatidylinositol (PI) and the activation of PI kinases (14). A primary downstream target of the PI pathway is protein kinase B (PKB/Akt), which has been implicated in cyclin D1 protein stabilization.

To examine the roles of both the MAPK pathway as well as the PI3-K (phosphatidylinositol 3-kinase) cascade, small molecule inhibitors were utilized. Last year, data was presented showing that 50 μ M PD098059, a MEK1 inhibitor (immediately upstream of MAPK), and 50 μ M LY294002, an inhibitor of PI3-K activity, prevented cell cycle progression of MCF-7 cells in response to estrogen stimulation. Further studies with these compounds suggested that PI3-K and MAPK activity were not required for transcriptional regulation of immediate early gene synthesis, but were essential for the cyclin D1 protein accumulation. These studies lead to the conclusion that estrogen initiates mitogenesis by inducing the transcription of immediate early genes, but cytoplasmic signaling cascades play an important role in the control of subsequent events in the cell cycle.

Additional Studies in the Role of Cytoplasmic Signaling Pathways in Estrogen-Induced Mitogenesis

Drug Dosage/Toxicity

As reported last year, the concentrations of inhibitory molecules being employed in these studies were neither cytotoxic nor pro-apoptotic to MCF-7 cells after 24 hours. However, dose response curves demonstrated that 5 μ M LY294002 was as potent as the 50 μ M concentration, and, for this reason, experiments were repeated with this dose. Furthermore, the commercial availability of U0126, an inhibitor of active and inactive MEK1 as well as MEK2, provided another means to insure that observations were specific for inhibition of the MAPK cascade rather than nonspecific effects of the drugs. Titration experiments determined that 25 μ M of U0126 was a potent inhibitor of estrogen-induced mitogenesis without cytotoxic or apoptotic effects.

An additional control for drug specificity was performed by examining the "relative health" of MCF-7 cells after exposure to the small molecule inhibitors. MCF-7 cells were treated for 24 hours in the presence of the PD098059, LY294002, U0126, or ICI 182,780 (an ER antagonist) at which time the cells were washed three times and stimulated with estrogen. Cell cycle progression occurred in all samples, except those treated with the estrogen antagonist, suggesting that the drugs impacting signaling cascades

were acting specifically on their reported pathways and that the inhibition was not irreversible. One reported mechanism for ICI 182,780 function is degradation of the ER (15). Thus, a failure for estrogen to elicit a mitogenic response in cells treated with ICI is not surprising since accumulation of ER protein must occur prior to the cells being receptive to estrogen stimulation.

Estrogen-Mediated Transcription in the Presence of MEK1/2 and PI3-K Inhibitors

The most well understood mode of estrogen action is the transcriptional activation of genes containing estrogen response elements (EREs). Among the genes containing putative EREs are several key cell cycle regulatory genes, *c-myc*, *c-fos*, and cyclin D1 (1, 3, 16). If the PI3-K and MAPK inhibitors affected transcriptional regulation by the estrogen receptor, they could stop cell cycle progression by preventing the induction of these genes. To determine if the effects of PD098059, U0126, and LY294002 on estrogen-stimulated mitogenesis were due to interference with ER-mediated transcriptional activity, we initially measured estrogen-induced expression from functional EREs. MCF-7 cells were transfected with a luciferase gene under the control of either a naturally occurring (vitellogenin, TK-ERE) or artificial estrogen-responsive promoter (3X-ERE) and cell extracts were harvested 24 hours later. In the absence of drugs, estrogen induced a five- to six-fold increase in luciferase activity as opposed to near basal levels seen in the presence of the ER antagonist, ICI 182,780. The MEK1 and PI3-K inhibitors decreased transcription by approximately 50% while inhibition of the protein kinase A (PKA) or protein kinase C (PKC) cascades had no impact on ER-mediated transcription. Therefore, there is some correlation between estrogen-mediated transcription in the reporter gene assay and cell cycle inhibition by these compounds.

The levels of the estrogen receptor itself may be decreasing in response to these compounds, which would account for the decline in transcriptional activity. Therefore, we measured the levels of ER by immunoblotting over the course of a 24-hr treatment regimen with the inhibitory molecules. ER is known to decline in response to estrogen treatment (17, 18), and we also observed this phenomenon since the levels of ER protein were reduced compared to the resting levels in starved cells after 24 hours. Treatment with PD098059 itself for 24 hours showed no decrease in ER levels, but when incubated in the presence of estrogen a decrease in ER levels, comparable to estrogen alone, was observed. LY294002 did result in some diminution of ER protein regardless of the presence or absence of estrogen. These studies on the impact of small molecule inhibitors on ER protein levels suggest that the effects observed with MAPK inhibitors are completely independent of ER levels. However, the lower ER levels in the presence of LY294002 suggests that the cell cycle arrest noted with this compound may result from degradation of estrogen's cognate receptor.

The decreased ER levels observed in the presence of LY294002 occurred between 9 and 24 hours after the addition of the drug, whereas the diminishment in the presence of ICI 182,780 was more pronounced and more rapid (occurring within the first 9 hours). This observation correlates with the moderate suppressive effect the PI3-K inhibitor had on estrogen-mediated transcription measured by reporter gene assay as compared to the complete loss of transcriptional activity noted with the ER antagonist. Furthermore, these assays were performed after 24 hours of treatment, at which time the cells are largely growth arrested. Decreased ER transcription may be a secondary effect of the arrest rather than a direct effect of the kinase inhibitors. Expression of immediate early genes occurs rapidly after estrogen treatment; therefore, we measured the expression of these genes directly. By Northern blotting, we observed maximal expression of the two putative estrogen-responsive immediate early genes, *c-myc* and *c-fos*, within one hour of estrogen treatment. Levels of *c-myc* remained highly elevated at 2 hours and declined by 6 hours after treatment while *c-fos* levels declined more rapidly. The ICI antiestrogen completely inhibited the induction of both *myc* and *fos* as expected. The PKA and PKC inhibitory controls, as well as PD098059, had no effect on the kinetics or magnitude of this induction. LY294002 did not prevent, but prolonged, the time needed to attain maximal expression of both genes. In the presence of the LY compound, *myc* and *fos* were significantly induced at 1 hour, however, a further increase in levels was observed at later time points. Levels of *myc* and *fos* protein were consistent with

the transcriptional induction of these genes. Where the pure antiestrogen completely inhibited immediate early gene expression, the kinase inhibitors allowed induction of both c-myc and c-fos, suggesting that the cell cycle block occurs after immediate early gene synthesis.

The Effects of PI3-K and MAPK Inhibitors on Estrogen-Induced Delayed-Early Cell Cycle Events

Increased cyclin D1 Expression is considered to be a delayed-early cell cycle event occurring after immediate early genes are induced. The accumulation of cyclin D1 protein levels after estrogen stimulation is a critical event in cell cycle progression (19). In addition, overexpression of cyclin D1 can reverse cell cycle arrest in ER+ cells that was accomplished by antiestrogen treatment. As detailed last year, estrogen treatment of serum starved MCF-7 cells resulted in a 3-fold increase in cyclin D1 levels by 6 hours. LY294002, PD098059, and ICI 182,780 prevented cyclin D1 accumulation.

Downstream effects of cyclin D1 induction, in response to estrogen stimulation, include activation of cyclinE/cdk2 complexes and hyperphosphorylation of Rb (see Introduction). Experiments were performed to examine both of these phenomena. Activity of cdk2 was assayed by stimulating MCF-7 cells in the presence or absence of the small molecule inhibitors for 24 hours. Cells were then lysed and cdk2 was immunoprecipitated and incubated with histone H1 (a substrate for cdk2's kinase activity) in the presence of [γ -³²P] dATP. Phosphorylation of histone H1 was determined by electrophoresis of the reaction on a 15% polyacrylamide gel and visualization by autoradiography. Estrogen alone stimulated a dramatic increase in cdk2 activity compared to serum starved samples, whereas, LY294002, PD098059, U0126, and ICI 182,780 all inhibited any noticeable increase in phosphorylation of histone H1. Not surprisingly, these drugs also prevented the hyperphosphorylation of Rb, which is required for cell cycle progression into the DNA synthesis stage. Therefore, it appears that the primary effect of PI3-K and MAPK inhibitors on estrogen induced cell cycle progression can be placed at or before the level of cyclin D1 induction (which is also prior to the decrease of ER levels noted with LY294002 treatment).

The Effect of Estrogen on the Activation of the MAPK and PI3-K Cascades

Inhibition of the PI3-K and MAPK cascades prevented efficient estrogen induced cell cycle entry in MCF-7 cells. Therefore, we investigated whether estrogen treatment activates these signaling pathways (9-13). Several recent reports have demonstrated that the MAP kinase pathway is activated by estrogen in an ER dependent fashion. MEK1 phosphorylates a threonine and a tyrosine residue in the regulatory sites of Erk1 and Erk2 resulting in the activation of these MAP kinases (reviewed in 20). We performed a series of experiments to determine whether Erk1 and/or Erk2 were activated under our conditions. The dually phosphorylated forms of Erk1 and Erk2 are specifically recognized on an immunoblot using a phospho-specific monoclonal antibody while total Erk1 and 2 are detected using a separate antibody after stripping and reprobing the same blot. Compared to untreated, serum-starved MCF-7 cells, EGF (epidermal growth factor) induced a dramatic increase in phosphorylated Erk1 and 2. Under the same conditions, 2×10^{-8} M estradiol, the most prevalent estrogen produced by the ovaries, had no effect on the levels of activated Erk 1 or 2. A number of repetitions of this experiment failed to show more than a 1.5-fold induction at any time point (from 1-20 minutes after treatment) or at any cell density. The strong activation of Erk1 and 2 by EGF was decreased but not entirely inhibited by the addition of PD098059, as previously shown (21). The ICI antiestrogen and the PI3-K inhibitor had no effect on EGF mediated activation. While estrogen failed to activate MAPK, PD098059 and U0126 completely inhibited the basal levels of phospho-Erk1 and 2. Neither ICI 182,780 nor LY294002 had any effect on active MAPK levels in estrogen or EGF stimulated cells.

Protein kinase B (PKB/Akt) is a primary downstream target of PI3-K activation and has been implicated in cyclin D1 protein stabilization (22). Stimulation with 30ng/ml insulin-like growth factor I (IGF-I), a known activator of PI3-kinase in MCF-7 cells (23), led to a pronounced increase in the phosphorylated (active) form of PKB as detected by a phosphospecific antibody. Treatment with estrogen had no effect on activated PKB levels, suggesting that PI3-kinase pathway does not respond to this hormone. The PI3-K drug was a potent inhibitor of PKB activation in all instances; it reduced both

the IGF-I induced and the basal levels of phospho-PKB to below the limit of detection. Therefore, estrogen fails to induce either the MAPK or PI3-kinase pathways to an appreciable degree; however, specific inhibitors reduce basal levels of the activated enzymatic substrates for these compounds to below the levels that are found in starved cells.

Summary/Conclusions

In the work detailed above, we found that disruption of the PI3 and MAP kinase cascades by specific inhibitors prevented or reduced the ability of MCF-7 cells to enter S phase in response to estrogen. The small molecule inhibitors of these pathways arrested cells in G1 and did not induce any significant cytotoxicity. We did observe a modest effect on estrogen-mediated transcription assay on artificial estrogen response elements; however, the immediate early genes *c-myc* and *c-fos* were induced by estrogen even in the presence of these drugs. Both the PI3-K and the MAPK inhibitors prevent cyclin D1 expression, which typically increases shortly after the immediate early genes are induced in mitogen stimulated cells. The lack of cyclin D1 accumulation also correlated with an absence of cdk2 activity and retinoblastoma phosphorylation. We concluded that inhibition of estrogen-mediated mitogenesis by these drugs was likely due to this repression of cyclin D1. Finally, we also demonstrated that estrogen does not measurably activate either PKB or MAPK under conditions that result in a mitogenic response. The mechanism by which inhibitors of these pathways impacts estrogen activity is open to question; however, we hypothesized that estrogen initiates mitogenesis by inducing the transcription of immediate early genes, but MAPK and PI3-K play an important role in the control and regulation of subsequent cell cycle events.

References

1. Dubik, D., and Shiu, R. P. C. Mechanism of estrogen activation of *c-myc* oncogene expression. *Oncogene*, 7: 1587-1594, 1992.
2. Hyder, S. M., Nawaz, Z., Chiappetta, C., Yokoyama, K., and Stancel, G. M. The protooncogene *c-jun* contains an unusual estrogen-inducible enhancer within the coding sequence. *J Biol Chem*, 270: 8506-13, 1995.
3. Weisz, A., and Rosales, R. Identification of an estrogen response element upstream of the human *c-fos* gene that binds the estrogen receptor and the AP-1 transcription factor. *Nucleic Acids Res*, 18: 5097-106, 1990.
4. Matsushime, H., Quelle, D. E., Shurtleff, S. A., Shibuya, M., Sherr, C. J., and Kato, J. Y. D-type cyclin-dependent kinase activity in mammalian cells. *Mol Cell Biol*, 14: 2066-76, 1994.
5. Meyerson, M., and Harlow, E. Identification of G1 kinase activity for *cdk6*, a novel cyclin D partner. *Mol Cell Biol*, 14: 2077-86, 1994.
6. Connell-Crowley, L., Harper, J. W., and Goodrich, D. W. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. *Mol Biol Cell*, 8: 287-301, 1997.
7. Polyak, K., Kato, J. Y., Solomon, M. J., Sherr, C. J., Massague, J., Roberts, J. M., and Koff, A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. *Genes Dev*, 8: 9-22, 1994.
8. Reynisdottir, I., Polyak, K., Iavarone, A., and Massague, J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. *Genes Dev*, 9: 1831-45, 1995.
9. DiDomenico, M., Castoria, G., Bilancio, A., Migliaccio, A., and Auricchio, F. Estradiol activation of human colon carcinoma-derived Caco-2 cell growth. *Cancer Res*, 56: 4516-4521, 1996.

10. Endoh, H., Sasaki, H., Maruyama, K., Takeyama, K., Waga, I., Shimizu, T., Kato, S., and Kawashima, H. Rapid activation of MAP kinase by estrogen in the bone cell line. *Biochem Biophys Res Commun*, 235: 99-102, 1997.
11. Migliaccio, A., Domenico, M. D., Castoria, G., Falco, A. d., Bontempo, P., Nola, E., and Auricchio, F. Tyrosine kinase/p21^{ras}/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. *EMBO J*, 15: 1292-1300, 1996.
12. Singh, M., Setalo, G., Jr., Guan, X., Warren, M., and Toran-Allerand, C. D. Estrogen-induced activation of mitogen-activated protein kinase in cerebral cortical explants: convergence of estrogen and neurotrophin signaling pathways. *J Neurosci*, 19: 1179-88, 1999.
13. Watters, J., Campbell, J., Cunningham, M., Krebs, E., and Dorsa, D. Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. *Endocrinology*, 138: 4030-3, 1997.
14. Etindi, R. N., Manni, A., and Martel, J. The effects of TGF- α and 17 beta-estradiol on polyphosphoinositide metabolism in MCF-7 breast cancer cells. *Breast Cancer Res Treat*, 24: 61-70, 1992.
15. Van Den Bemd, G. J., Kuiper, G. G., Pols, H. A., and Van Leeuwen, J. P. Distinct effects on the conformation of estrogen receptor alpha and beta by both the antiestrogens ICI 164,384 and ICI 182,780 leading to opposite effects on receptor stability. *Biochem Biophys Res Commun*, 261: 1-5, 1999.
16. Altucci, L., Addeo, R., Cicatiello, L., Dauvois, S., Parker, M. G., Truss, M., Beato, M., Sica, V., Bresciani, F., and Weisz, A. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. *Oncogene*, 12: 2315-2324, 1996.
17. Ree, A. H., Landmark, B. F., Eskild, W., Levy, F. O., Lahooti, H., Jahnsen, T., Aakvaag, A., and Hansson, V. Autologous down-regulation of messenger ribonucleic acid and protein levels for estrogen receptors in MCF-7 cells: an inverse correlation to progesterone receptor levels. *Endocrinology*, 124: 2577-83, 1989.
18. Read, L. D., Greene, G. L., and Katzenellenbogen, B. S. Regulation of estrogen receptor messenger ribonucleic acid and protein levels in human breast cancer cell lines by sex steroid hormones, their antagonists, and growth factors. *Mol Endocrinol*, 3: 295-304, 1989.
19. Planas-Silva, M. D., and Weinberg, R. A. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. *Mol Cell Biol*, 17: 4059-4069, 1997.
20. Ahn, N. G., Seger, R., and Krebs, E. G. The mitogen-activated protein kinase activator. *Curr Opin Cell Biol*, 4: 992-9, 1992.
21. Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., and Saltiel, A. PD 098059 is a specific inhibitor of the activation of mitogen- activated protein kinase kinase in vitro and in vivo. *J Biol Chem*, 270: 27489-27494, 1995.
22. Muise-Helmericks, R. C., Grimes, H. L., Bellacosa, A., Malstrom, S. E., Tsichlis, P. N., and Rosen, N. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. *J Biol Chem*, 273: 29864-72, 1998.
23. Dufourmy, B., Alblas, J., van Teeffelen, H. A., van Schaik, F. M., van der Burg, B., Steenbergh, P. H., and Sussenbach, J. S. Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. *J Biol Chem*, 272: 31163-71, 1997.

Appendix

Key Research Accomplishments

- ◆ Identification of signaling cascades important in estrogen-induced mitogenesis.
- ◆ Narrowing of the time interval (in terms of the cell cycle clock) when these kinases are necessary for DNA synthesis in response to estrogen stimulation in MCF-7 cells.

Reportable Outcomes

- ◆ The data presented in this annual report has been submitted to the journal of Cell Growth and Differentiation and reviewed. This summary also includes the additional experiments requested by the reviewers and will be resubmitted by the end of September 1999.
- ◆ A poster of these experiments will be presented at the 1999 Duke University Medical Center Graduate Research Symposium in October.



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MD 21702-5012

REPLY TO
ATTENTION OF

MCMR-RMI-S (70-1y)

15 May 03

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl


PHYLLIS M. RINEHART
Deputy Chief of Staff for
Information Management

ADB266022	ADB265793
ADB260153	ADB281613
ADB272842	ADB284934
ADB283918	ADB263442
ADB282576	ADB284977
ADB282300	ADB263437
ADB285053	ADB265310
ADB262444	ADB281573
ADB282296	ADB250216
ADB258969	ADB258699
ADB269117	ADB274387
ADB283887	ADB285530
ADB263560	
ADB262487	
ADB277417	
ADB285857	
ADB270847	
ADB283780	
ADB262079	
ADB279651	
ADB253401	
ADB264625	
ADB279639	
ADB263763	
ADB283958	
ADB262379	
ADB283894	
ADB283063	
ADB261795	
ADB263454	
ADB281633	
ADB283877	
ADB284034	
ADB283924	
ADB284320	
ADB284135	
ADB259954	
ADB258194	
ADB266157	
ADB279641	
ADB244802	
ADB257340	
ADB244688	
ADB283789	
ADB258856	
ADB270749	
ADB258933	